Similar articles

• Phase II study of alternating cytoreductive and cycle-active combination chemotherapy for metastatic breast cancer.

  Vogel CL, Love NH, East DR, Moore MR, Smalley RV. Vogel CL, et al. Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2077-9. Cancer Treat Rep. 1979. PMID: 526940
• The effect of postoperative radiotherapy on the feasibility of optimal dose adjuvant CMF chemotherapy in stage II breast carcinoma.

  Sulkes A, Brufman G, Rizel S, Weshler Z, Biran S, Fuks Z. Sulkes A, et al. Int J Radiat Oncol Biol Phys. 1983 Jan;9(1):17-21. doi: 10.1016/0360-3016(83)90202-x. Int J Radiat Oncol Biol Phys. 1983. PMID: 6687724 No abstract available.
• Advanced breast cancer: high-dose chemotherapy and bone marrow autotransplants.

  Antman K, Gale RP. Antman K, et al. Ann Intern Med. 1988 Apr;108(4):570-4. doi: 10.7326/0003-4819-108-4-570. Ann Intern Med. 1988. PMID: 3279894 Review.
• [Efficacy of zoledronate in treating persisting isolated tumor cells in bone marrow in patients with breast cancer. A phase II pilot study].

  Rack B, Schindlbeck C, Strobl B, Sommer H, Friese K, Janni W. Rack B, et al. Dtsch Med Wochenschr. 2008 Feb;133(7):285-9. doi: 10.1055/s-2008-1046707. Dtsch Med Wochenschr. 2008. PMID: 18253918 Clinical Trial. German.
• [Concurrent chemoradiotherapy for advanced breast cancer].

  Karasawa K, Ito K, Hirowatari H, Saito AI, Izawa H. Karasawa K, et al. Nihon Rinsho. 2007 Jun 28;65 Suppl 6:402-6. Nihon Rinsho. 2007. PMID: 17682184 Review. Japanese. No abstract available.